:strip_icc()/s03.video.glbimg.com/x720/9065894.jpg)
[ad_1]
The main points of the preliminary strategy are shown below:
- First phase: health workers, elderly population over 75 years old, people 60 years and over living in long-term care facilities (such as nursing homes and psychiatric institutions) and indigenous population
- Second stage: people from 60 to 74 years old.
- Third phase– People with comorbidities that are more likely to make the disease worse (such as having chronic kidney and cardiovascular disease).
- Fourth phase: teachers, security and rescue forces, prison staff and people deprived of liberty.
The ministry hopes to immunize 109.5 million people. The estimate is that vaccination will occur “in two doses, according to the provisions of the immunization schedules for immunizers already guaranteed by the Ministry of Health – Fiocruz / AstraZeneca and through the Covax Facility alliance.”
The so-called “preliminary definitions of the strategy” do not mention the CoronaVac vaccine from Chinese pharmaceutical Sinovac, which is in the final phase of testing and is already expected to be distributed in Brazil. The São Paulo government signed an agreement to acquire 46 million doses and transfer technology to the Butantan Institute.
The Ministry of Health recalled that the government currently has 142.9 million doses of vaccines guaranteed through the agreements Fiocruz / AstraZeneca (100.4 million) and Covax Facility (42.5 million). But nevertheless, no vaccine was recorded in the Anvisa.
Not to mention CoronaVac, the government also noted that, “last month, the Ministry of Health hosted meetings with representatives of Pfizer BioNTech, Moderna, Bharat Biotech (covaxin) and Instituto Gamaleya (sputinik V), which also have vaccines in the clinical research stage. advanced, technical and logistical approach “.
This Tuesday, the Secretary of Sanitary Surveillance of the Ministry of Health, Arnaldo Medeiros, said that the vaccination plan will aim to adopt immunizers that are thermostable, that is, that do not need very low storage temperatures. as with the Pfizer and Moderna candidates.
